William Hapworth, MD
Psychiatry · New York, NYNPI 1861536104
Payments from drug & device makers
What this record shows
Livanova USA, Inc. accounts for 65.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $1,712 and has fallen 91.7% since, to $142 in 2025.
Across 30 payments — averaging $118.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- Merck$1K
- Johnson & Johnson$142
- Siemens Medical Solutions USA, Inc.$95
Across 279 payments — averaging $4784.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$756K
- Genentech, Inc.$435K
- Sage Therapeutics, LLC$92K
- Janssen Research & Development, LLC$41K
- Biohaven Pharmaceutical Holding Company Ltd.$8K
- Biohaven Pharmaceuticals, Inc.$2K
What the payments were for
- Travel & lodging$1,79551%
- Food & beverage$1,75949%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 20 | $2,312 |
| Merck | 8 | $1,005 |
| Johnson & Johnson | 1 | $142 |
| Siemens Medical Solutions USA, Inc. | 1 | $95 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,554 in reported general payments places this provider in the 85th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 42 | $1,496 |
| Lamotrigine | 19 | $771 |
| Fluoxetine Hcl | 57 | $730 |
| Mirtazapine | 23 | $535 |
| Clonazepam | 28 | $456 |
| Trazodone Hcl | 28 | $359 |
| Sertraline Hcl | 27 | $275 |
| Gabapentin | 20 | $220 |
| Risperidone | 14 | $209 |
| Escitalopram Oxalate | 16 | $115 |
| Citalopram HbrCitalopram Hydrobromide | 18 | $47 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New York
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Ulla Kristina LaaksoNew York$890K
- Kerry SulkowiczNew York$435K
- Ralph AquilaNew York$143K
- Daniel KarlinNew York$101K
- David StraussNew York$95K
- Anissa Abi-DarghamNew York$94K
- Robin McGarryNew York$69K
- Nicole AllenNew York$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.